A new study reports that reovirus has the potential to treat certain lung cancer patients, when the reovirus is combined with two other substances known as paclitaxel and carboplatin.

The trial is being conducted at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio (CTRC.

The study is a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.